SD Cancer Research Results

SD, Stable Disease: Click to Expand ⟱
Source:
Type:
Stable Disease
Scientific Papers found: Click to Expand⟱
7986- itraC,    Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma
- Trial, BCC, NA
Dose↝, receive oral itraconazole 200 mg twice per day for 1 month (cohort A) or 100 mg twice per day for an average of 2.3 months (cohort B).
TumCP↓, Itraconazole reduced cell proliferation by 45% (P = .04), HH pathway activity by 65% (P = .03), and reduced tumor area by 24%
HH↓,
TumVol↓,
SD↑, Of eight patients with multiple nonbiopsied tumors, four achieved partial response, and four had stable disease

8127- LF,    Phase I trial of oral talactoferrin alfa in refractory solid tumors
- Trial, Var, NA
Imm↑, Lactoferrin is an iron-binding glycoprotein first identified in breast milk as a protein product of mammary epithelial cells. Its immunomodulatory functions include activation of NK
NK cell↑,
Dose↝, Ten adult patients with progressive advanced solid tumors who had failed conventional chemotherapy were administered oral TLF at doses from 1.5 to 9 g/day, using a 2 weeks on, 2 weeks off schedule.
toxicity↓, Talactoferrin was very well tolerated. No hematological, hepatic, or renal toxicities were reported.
IL18↑, Following oral administration, significant levels of talactoferrin were undetectable in circulation, but a statistically significant increase in circulating IL-18, a pharmacodynamic indicator of talactoferrin activity, was observed.
SD↑, Of the eight patients who were radiologically evaluable, five (63%) had stable disease by RECIST criteria two months after start of therapy, including one patient with a minor response.
TumCG↓, Seven patients (88%) had a decrease in their tumor growth rate.
OS↑, The three patients with non-small cell lung cancer (NSCLC) all survived for at least one year following the start of talactoferrin monotherapy.

2038- PB,    A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies
- Trial, Var, NA
Dose∅, The recommended Phase II dose is 27 g/day.
*toxicity↝, Nonoverlapping dose-limiting toxicities of nausea/vomiting and hypocalcemia were seen at 36 g/day
BioAv↑, The p.o. bioavailability of PB was 78% for all dose levels, and the biologically active concentration of 0.5 mM was achieved at all dose levels.
SD↑, No partial remission or complete remission was seen, but 7 patients had stable disease for more than 6 months while on the drug.


Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Transcription & Epigenetics(tgid=7) ⓘ

SD↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

HH↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

TumCP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL18↑, 1,   Imm↑, 1,   NK cell↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   Dose↝, 2,   Dose∅, 1,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 1,   toxicity↓, 1,   TumVol↓, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


Functional Outcomes(tgid=23) ⓘ

toxicity↝, 1,  
Total Targets: 1

Scientific Paper Hit Count for: SD, Stable Disease
1 itraconazole
1 Lactoferrin/Talactoferrin
1 Phenylbutyrate
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1236  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page